Loading...
XKRX271980
Market cap121mUSD
Jan 08, Last price  
12,120.00KRW
1D
0.17%
1Q
-18.66%
IPO
-75.12%
Name

Jeil Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XKRX:271980 chart
P/E
35.29
P/S
0.24
EPS
343.46
Div Yield, %
0.41%
Shrs. gr., 5y
1.84%
Rev. gr., 5y
2.98%
Revenues
726.39b
+0.58%
594,715,654,750617,279,879,535371,591,762,660627,074,758,250671,406,874,750691,324,836,680700,693,229,140722,229,924,460726,393,758,030
Net income
5.00b
P
9,761,370,9237,890,255,0241,067,594,9601,889,032,640-10,584,593,1606,916,120,970-14,985,617,760-15,009,013,7405,004,744,920
CFO
-4.98b
L-67.12%
2,743,173,85711,362,901,636-4,209,794,00021,453,352,45028,957,623,940-19,046,087,11019,100,245,510-15,146,989,610-4,980,678,286
Dividend
Dec 27, 202350 KRW/sh
Earnings
Feb 18, 2025

Profile

Jeil Pharmaceutical Co.,Ltd develops and supplies pharmaceutical products primarily in South Korea. It provides products in the areas of antibiotic, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamine. The company also exports its products to approximately 40 countries in ASEAN, Central and South America, Africa, and internationally. Jeil Pharmaceutical Co.,Ltd was founded in 1959 and is headquartered in Seoul, South Korea.
URL
https://www.jeilpharm.co.kr/
IPO date
Jul 17, 2017
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
726,393,758
0.58%
722,229,924
3.07%
Cost of revenue
664,346,812
681,211,972
Unusual Expense (Income)
NOPBT
62,046,946
41,017,953
NOPBT Margin
8.54%
5.68%
Operating Taxes
(3,284,477)
1,762,368
Tax Rate
4.30%
NOPAT
65,331,424
39,255,584
Net income
5,004,745
-133.34%
(15,009,014)
0.16%
Dividends
(728,378)
(947,735)
Dividend yield
0.29%
0.31%
Proceeds from repurchase of equity
(396,983)
BB yield
0.13%
Debt
Debt current
66,718,274
44,908,020
Long-term debt
10,850,307
12,717,420
Deferred revenue
227,111
Other long-term liabilities
7,671,664
26,967,503
Net debt
34,567,910
16,785,992
Cash flow
Cash from operating activities
(4,980,678)
(15,146,990)
CAPEX
(6,096,733)
(16,958,190)
Cash from investing activities
(11,918,615)
(12,924,123)
Cash from financing activities
18,765,520
33,617,868
FCF
72,450,885
57,191,433
Balance
Cash
35,657,543
31,588,692
Long term investments
7,343,127
9,250,756
Excess cash
6,680,983
4,727,952
Stockholders' equity
6,564,651
5,590,146
Invested Capital
229,470,199
227,365,353
ROIC
28.60%
18.04%
ROCE
26.29%
17.67%
EV
Common stock shares outstanding
14,572
14,575
Price
17,100.00
-18.57%
21,000.00
-37.96%
Market cap
249,172,941
-18.59%
306,070,317
-38.11%
EV
282,202,903
320,544,508
EBITDA
71,814,046
49,904,188
EV/EBITDA
3.93
6.42
Interest
6,033,022
3,009,253
Interest/NOPBT
9.72%
7.34%